Vital KSK Holdings, Inc. (VKSKF)
OTCMKTS
· Delayed Price · Currency is USD
8.60
0.00 (0.00%)
May 2, 2025, 4:00 PM EDT
Vital KSK Holdings Revenue
Vital KSK Holdings had revenue of 163.60B JPY in the quarter ending December 31, 2024, with 5.76% growth. This brings the company's revenue in the last twelve months to 599.25B, up 2.35% year-over-year. In the fiscal year ending March 31, 2024, Vital KSK Holdings had annual revenue of 587.48B with 1.33% growth.
Revenue (ttm)
599.25B JPY
Revenue Growth
+2.35%
P/S Ratio
0.12
Revenue / Employee
161.74M JPY
Employees
3,705
Market Cap
442.71M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
Mar 31, 2020 | 562.51B | 2.79B | 0.50% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |